RemeGen Co., Ltd. (SHA:688331)

Market Cap	18.35B
Revenue (ttm)	1.72B
Net Income (ttm)	-1.47B
Shares Out	n/a
EPS (ttm)	-2.73
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,348,323
Average Volume	4,677,944
Open	40.39
Previous Close	39.80
Day's Range	38.98 - 43.20
52-Week Range	22.37 - 59.58
Beta	0.41
RSI	71.79
Earnings Date	Mar 28, 2025

About RemeGen

RemeGen Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologics for the treatment of autoimmune, oncology, and ophthalmic diseases with unmet medical needs in Mainland China and the United States. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus (SLE) an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. Its products in various stages of development include RC18, which is under phase III clinical tri...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 3,615
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688331

Financial Performance

In 2024, RemeGen's revenue was 1.72 billion, an increase of 58.40% compared to the previous year's 1.08 billion. Losses were -1.47 billion, -2.87% less than in 2023.